arsenic trioxide has been researched along with arginyl-glycyl-aspartic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fei, W; Han, S; Li, F; Tao, J; Wang, X; Wei, Y; Zhang, Y; Zheng, H; Zhu, J | 1 |
| Han, S; Li, F; Lu, Y; Ma, R; Ping, Y; Tang, H; Xu, X; Zhang, Y; Zheng, H; Zou, J | 1 |
| Cheng, Y; Fan, X; Li, F; Lu, Y; Ma, R; Piao, JG; Shi, X; Zheng, H; Zou, J | 1 |
3 other study(ies) available for arsenic trioxide and arginyl-glycyl-aspartic acid
| Article | Year |
|---|---|
RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liposomes; Liver Neoplasms; MCF-7 Cells; Mice; Nanoparticles; Oligopeptides; Oxides; Silicon Dioxide | 2017 |
A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blood-Brain Barrier; Cell Cycle; Cell Line, Tumor; Dendrimers; Drug Carriers; Drug Delivery Systems; Drug Liberation; Endocytosis; Glioma; Humans; Male; Mice; Oligopeptides; Oxides; Polyethylene Glycols; Rabbits; Rats; Static Electricity; Treatment Outcome | 2018 |
iRGD and TGN co-modified PAMAM for multi-targeted delivery of ATO to gliomas.
Topics: Antineoplastic Agents; Arsenic Trioxide; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line; Dendrimers; Drug Carriers; Drug Delivery Systems; Glioma; Humans; Oligopeptides; Tissue Distribution | 2020 |